Skip to content
Review

Abstract 6864: Reduced Dose versus Full Dose Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: Patients with venous thromboembolism (VTE) who complete initial anticoagulation often require extended therapy to prevent recurrence, but this must be balanced against bleeding risks. While reduced-dose direct oral anticoagulants (DOACs) are increasingly used, their comparative efficacy and safety versus full-dose DOACs across diverse populations including cancer-associated thrombosis remains debated. Methods: We searched PubMed, EMBASE, and Cochrane CENTRAL for randomized controlled trials (RCTs) comparing reduced-dose DOACs (apixaban 2.5 mg BID or rivaroxaban 10 mg OD) against full-dose DOACs for extended VTE treatment (≥6 months). The primary efficacy outcome was recurrent VTE, and the primary safety outcome was major bleeding. Secondary outcomes included clinically relevant non-major bleeding (CRNMB) and all-cause mortality. We pooled risk ratios (RRs) with 95% confidence intervals (CIs) using a DerSimonian-Laird random-effects model. A pre-specified sensitivity analysis was conducted by adding the recently published HI-PRO trial, which compared reduced-dose apixaban to placebo. Results: The primary analysis included 5 RCTs (AMPLIFY-EXT, EINSTEIN CHOICE, RENOVE, EVE, API-CAT) comprising 8,781 patients. Compared to full-dose DOACs, reduced-dose DOACs demonstrated comparable efficacy in preventing recurrent VTE (RR 0.91, 95% CI 0.66-1.26; I 2 =0.0%) and comparable all-cause mortality (RR 0.89, 95% CI 0.75-1.06; I 2 =0.0%). For safety, reduced-dose DOACs showed a trend toward lower major bleeding (RR 0.72, 95% CI 0.50-1.04; I 2 =0.0%) and significantly reduced CRNMB (RR 0.72, 95% CI 0.61-0.85; p<0.001; I 2 =0.0%). In the sensitivity analysis incorporating the placebo-controlled HI-PRO trial (total 6 RCTs, n=9,381), the pooled RR for recurrent VTE shifted to 0.71 (95% CI 0.41-1.21), but introduced substantial heterogeneity (I 2 =64.7%), driven entirely by the placebo comparator in HI-PRO (RR 0.13, 95% CI 0.05-0.37). Mortality remained consistent in the 6-study analysis (RR 0.88, 95% CI 0.75-1.05; I 2 =0.0%). Conclusion: For the extended treatment of VTE, reduced-dose DOACs are as effective as full-dose DOACs in preventing recurrence and mortality, while significantly reducing the risk of clinically relevant non-major bleeding by 28%. The inclusion of placebo-controlled data introduces significant heterogeneity, highlighting that reduced-dose DOACs are vastly superior to placebo for efficacy, but non-inferior to full-dose DOACs with an optimized safety profile. These findings support the routine use of reduced-dose DOACs for extended VTE secondary prevention across broad patient populations.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.